Sabrina Paganoni

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7422537/publications.pdf

Version: 2024-02-01

107	3,819	159525	149623
papers	citations	30 h-index	56 g-index

111	111	111	4779
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Muscle synergy patterns as physiological markers of motor cortical damage. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 14652-14656.	3.3	479
2	Trial of Sodium Phenylbutyrateâ€“Taursodiol for Amyotrophic Lateral Sclerosis. New England Journal of Medicine, 2020, 383, 919-930.	13.9	299
3	Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle and Nerve, 2011, 44, 20-24.	1.0	265
4	Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 453-456.	1.1	157
5	Assisting hand function after spinal cord injury with a fabric-based soft robotic glove. Journal of NeuroEngineering and Rehabilitation, 2018, 15, 59.	2.4	155
6	Telehealth in Physical Medicine and Rehabilitation: A Narrative Review. PM and R, 2017, 9, S51-S58.	0.9	137
7	Longâ€term survival of participants in the <scp>CENTAUR</scp> trial of sodium phenylbutyrateâ€taursodiol in <scp>amyotrophic lateral sclerosis</scp>. Muscle and Nerve, 2021, 63, 31-39.	1.0	115
8	Uric acid levels predict survival in men with amyotrophic lateral sclerosis. Journal of Neurology, 2012, 259, 1923-1928.	1.8	99
9	Electrodiagnostic Evaluation of Myopathies. Physical Medicine and Rehabilitation Clinics of North America, 2013, 24, 193-207.	0.7	92
10	Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 186.	4.5	79
11	Urate as a Marker of Risk and Progression of Neurodegenerative Disease. Neurotherapeutics, 2017, 14, 148-153.	2.1	75
12	Integrated magnetic resonance imaging and [¹¹C]â€PBR28 positron emission tomographic imaging in amyotrophic lateral sclerosis. Annals of Neurology, 2018, 83, 1186-1197.	2.8	75
13	Rehabilitation in amyotrophic lateral sclerosis: Why it matters. Muscle and Nerve, 2014, 50, 4-13.	1.0	73
14	Neurite extension in central neurons: a novel role for the receptor tyrosine kinases Ror1 and Ror2. Journal of Cell Science, 2005, 118, 433-446.	1.2	71
15	Mortality Among Professional American-Style Football Players and Professional American Baseball Players. JAMA Network Open, 2019, 2, e194223.	2.8	63
16	Design and results of a smartphoneâ€based digital phenotyping study to quantify ALS progression. Annals of Clinical and Translational Neurology, 2019, 6, 873-881.	1.7	60
17	Comprehensive rehabilitative care across the spectrum of amyotrophic lateral sclerosis. NeuroRehabilitation, 2015, 37, 53-68.	0.5	53
18	Outcome measures in amyotrophic lateral sclerosis clinical trials. Clinical Investigation, 2014, 4, 605-618.	0.0	50

#	Article	IF	Citations
19	Ultra high-field (7tesla) magnetic resonance spectroscopy in Amyotrophic Lateral Sclerosis. PLoS ONE, 2017, 12, e0177680.	1.1	45
20	Integrated imaging of [11C]-PBR28 PET, MR diffusion and magnetic resonance spectroscopy 1H-MRS in amyotrophic lateral sclerosis. NeuroImage: Clinical, 2018, 20, 357-364.	1.4	45
21	New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures. Alzheimer's and Dementia, 2020, 16, 131-143.	0.4	45
22	Amyotrophic lateral sclerosis care and research in the United States during the <scp>COVID</scp>â€19 pandemic: Challenges and opportunities. Muscle and Nerve, 2020, 62, 182-186.	1.0	42
23	Palliative Care Issues in Amyotrophic Lateral Sclerosis. American Journal of Hospice and Palliative Medicine, 2016, 33, 84-92.	0.8	41
24	Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development. Annals of Neurology, 2022, 91, 165-175.	2.8	41
25	Experience with telemedicine in a multi-disciplinary ALS clinic. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 143-148.	1.1	39
26	Urate levels predict survival in amyotrophic lateral sclerosis: Analysis of the expanded Pooled Resource Openâ€Access ALS clinical trials database. Muscle and Nerve, 2018, 57, 430-434.	1.0	39
27	Developing multidisciplinary clinics for neuromuscular care and research. Muscle and Nerve, 2017, 56, 848-858.	1.0	38
28	Expression and subcellular localization of Ror tyrosine kinase receptors are developmentally regulated in cultured hippocampal neurons. Journal of Neuroscience Research, 2003, 73, 429-440.	1.3	37
29	Complementary and Alternative Therapies in Amyotrophic Lateral Sclerosis. Neurologic Clinics, 2015, 33, 909-936.	0.8	37
30	Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability. Muscle and Nerve, 2017, 56, 1077-1084.	1.0	37
31	Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 871-875.	0.9	37
32	Incidence of and Mortality From Amyotrophic Lateral Sclerosis in National Football League Athletes. JAMA Network Open, 2021, 4, e2138801.	2.8	35
33	Soft Robotic Glove with Integrated Sensing for Intuitive Grasping Assistance Post Spinal Cord Injury. , 2019, , .		34
34	Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2018, 5, 1522-1533.	1.7	31
35	Integration of a palliative care specialist in an amyotrophic lateral sclerosis clinic: Observations from one center. Muscle and Nerve, 2019, 60, 137-140.	1.0	30
36	Survival analyses from the <scp>CENTAUR</scp> trial in amyotrophic lateral sclerosis: Evaluating the impact of treatment crossover on outcomes. Muscle and Nerve, 2022, 66, 136-141.	1.0	30

#	Article	IF	Citations
37	Imaging of glia activation in people with primary lateral sclerosis. NeuroImage: Clinical, 2018, 17, 347-353.	1.4	29
38	A pilot trial of RNS60 in amyotrophic lateral sclerosis. Muscle and Nerve, 2019, 59, 303-308.	1.0	29
39	An integrated multi-omic analysis of iPSC-derived motor neurons from C9ORF72 ALS patients. IScience, 2021, 24, 103221.	1.9	27
40	Prediagnostic plasma metabolomics and the risk of amyotrophic lateral sclerosis. Neurology, 2019, 92, 10.1212/WNL.0000000000007401.	1.5	26
41	Cromolyn sodium delays disease onset and is neuroprotective in the SOD1G93A Mouse Model of amyotrophic lateral sclerosis. Scientific Reports, 2019, 9, 17728.	1.6	26
42	Preâ€morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosis. Muscle and Nerve, 2015, 52, 339-343.	1.0	25
43	Telemedicine to innovate amyotrophic lateral sclerosis multidisciplinary care: The time has come. Muscle and Nerve, 2019, 59, 3-5.	1.0	25
44	Optimizing telemedicine to facilitate amyotrophic lateral sclerosis clinical trials. Muscle and Nerve, 2020, 62, 321-326.	1.0	24
45	Adjusted cost analysis of video televisits for the care of people with amyotrophic lateral sclerosis. Muscle and Nerve, 2019, 60, 147-154.	1.0	23
46	Vitamin D levels are associated with gross motor function in amyotrophic lateral sclerosis. Muscle and Nerve, 2017, 56, 726-731.	1.0	22
47	Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial. NeuroImage: Clinical, 2021, 30, 102672.	1.4	21
48	Trials of Antidiabetic Drugs in Amyotrophic Lateral Sclerosis: Proceed with Caution?. Neurodegenerative Diseases, 2014, 13, 205-208.	0.8	20
49	Serum urate at trial entry and ALS progression in EMPOWER. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 120-125.	1.1	20
50	Prediagnostic Neurofilament Light Chain Levels in Amyotrophic Lateral Sclerosis. Neurology, 2021, 97, e1466-e1474.	1.5	20
51	Smartphone data during the <scp>COVID</scp>â€19 pandemic can quantify behavioral changes in people with <scp>ALS</scp>. Muscle and Nerve, 2021, 63, 258-262.	1.0	19
52	High-Fat and Ketogenic Diets in Amyotrophic Lateral Sclerosis. Journal of Child Neurology, 2013, 28, 989-992.	0.7	18
53	Causal inference methods to study gastric tube use in amyotrophic lateral sclerosis. Neurology, 2017, 89, 1483-1489.	1.5	18
54	Urate mitigates oxidative stress and motor neuron toxicity of astrocytes derived from ALS-linked SOD1 mutant mice. Molecular and Cellular Neurosciences, 2018, 92, 12-16.	1.0	18

#	Article	IF	Citations
55	Measuring the Impact of Research Using Conventional and Alternative Metrics. American Journal of Physical Medicine and Rehabilitation, 2019, 98, 331-338.	0.7	18
56	Functional Decline is Associated with Hopelessness in Amyotrophic Lateral Sclerosis (ALS). Journal of Neurology & Neurophysiology, 2017, 08, .	0.1	17
57	Primary lateral sclerosis (PLS) functional rating scale: PLSâ€specific clinimetric scale. Muscle and Nerve, 2020, 61, 163-172.	1.0	17
58	Imaging Neurochemistry and Brain Structure Tracks Clinical Decline and Mechanisms of ALS in Patients. Frontiers in Neurology, 2020, 11, 590573.	1.1	16
59	The Formation of Synapses in the Central Nervous System. Molecular Neurobiology, 2002, 26, 069-080.	1.9	15
60	Patient reported outcome measures (PROMs) in amyotrophic lateral sclerosis. Journal of Neurology, 2020, 267, 1754-1759.	1.8	15
61	Nutritional counseling with or without mobile health technology: a randomized open-label standard-of-care-controlled trial in ALS. BMC Neurology, 2019, 19, 104.	0.8	13
62	Differential subcellular localization of Ror tyrosine kinase receptors in cultured astrocytes. Glia, 2004, 46, 456-466.	2.5	12
63	Estimating Bradykinesia in Parkinson's Disease with a Minimum Number of Wearable Sensors. , 2017, , .		12
64	Pre-diagnostic plasma lipid levels and the risk of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 133-143.	1.1	12
65	The Impact of a Culinary Coaching Telemedicine Program on Home Cooking and Emotional Well-Being during the COVID-19 Pandemic. Nutrients, 2021, 13, 2311.	1.7	12
66	Association of spinocerebellar ataxia type 3 and spinocerebellar ataxia type 8 microsatellite expansions: Genetic counseling implications. Movement Disorders, 2008, 23, 154-155.	2.2	11
67	Patient reported outcomes in ALS: characteristics of the self-entry ALS Functional Rating Scale-revised and the Activities-specific Balance Confidence Scale. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 467-477.	1.1	10
68	Ultra-high field (7T) functional magnetic resonance imaging in amyotrophic lateral sclerosis: a pilot study. NeuroImage: Clinical, 2021, 30, 102648.	1.4	10
69	Using Smartphones to Reduce Research Burden in a Neurodegenerative Population and Assessing Participant Adherence: A Randomized Clinical Trial and Two Observational Studies. JMIR MHealth and UHealth, 2022, 10, e31877.	1.8	10
70	An expanded access protocol of <scp>RT001</scp> in amyotrophic lateral sclerosisâ€"Initial experience with a lipid peroxidation inhibitor. Muscle and Nerve, 2022, 66, 421-425.	1.0	10
71	Cooking Online With a Chef: Health Professionalsâ€™ Evaluation of a Live Culinary Coaching Module. Nutrition and Metabolic Insights, 2019, 12, 117863881988739.	0.8	9
72	Comparison of Two Clinical Upper Motor Neuron Burden Rating Scales in ALS Using Quantitative Brain Imaging. ACS Chemical Neuroscience, 2021, 12, 906-916.	1.7	9

#	Article	IF	Citations
73	Evidence-Based Physiatry. American Journal of Physical Medicine and Rehabilitation, 2020, 99, 764-765.	0.7	8
74	Statin Medications and Amyotrophic Lateral Sclerosis Incidence and Mortality. American Journal of Epidemiology, 2022, 191, 1248-1257.	1.6	7
75	What does body mass index measure in amyotrophic lateral sclerosis and why should we care?. Muscle and Nerve, 2012, 45, 612-612.	1.0	6
76	Development and validation of a machine-learning ALS survival model lacking vital capacity (VC-Free) for use in clinical trials during the COVID-19 pandemic. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 22-32.	1.1	6
77	Preface: promoting research in PLS: current knowledge and future challenges. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 1-2.	1.1	6
78	Clinical care and therapeutic trials in PLS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 67-73.	1.1	6
79	ALSUntangled #64: butyrates. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 638-643.	1.1	6
80	Disease Burden in Upper Motor Neuron Syndromes. Journal of Clinical Neuromuscular Disease, 2014, 16, 104-105.	0.3	5
81	Prediagnostic plasma branched chain amino acids and the risk of amyotrophic lateral sclerosis. Neurology, 2018, 92, 10.1212/WNL.0000000000006669.	1.5	5
82	The NEALS primary lateral sclerosis registry. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 74-81.	1.1	5
83	Exploring the Use of Educational Material About Shoulder Dysfunction. American Journal of Physical Medicine and Rehabilitation, 2018, 97, 379-382.	0.7	4
84	Recruitment of Patients With Amyotrophic Lateral Sclerosis for Clinical Trials and Epidemiological Studies: Descriptive Study of the National ALS Registryâ€™s Research Notification Mechanism. Journal of Medical Internet Research, 2021, 23, e28021.	2.1	4
85	Clinical Improvement of Monomelic Amyotrophy After Avoidance of Sustained Neck Flexion. Journal of Clinical Neuromuscular Disease, 2014, 15, 191-192.	0.3	3
86	Evidence-Based Physiatry. American Journal of Physical Medicine and Rehabilitation, 2018, 97, 531-532.	0.7	3
87	All-Cause and Cause-Specific Mortality Among Major League Baseball Players. JAMA Internal Medicine, 2019, 179, 1298.	2.6	3
88	Reply. Muscle and Nerve, 2015, 52, 691-691.	1.0	2
89	Outcome measures in the idiopathic inflammatory myopathies. Neurology, 2017, 89, 20-21.	1.5	2
90	Implementation of a Multifaceted Interactive Electrodiagnostic Medicine Workshop in a Physical Medicine and Rehabilitation Residency Program. American Journal of Physical Medicine and Rehabilitation, 2018, 97, 134-140.	0.7	2

#	Article	IF	Citations
91	Evidence-Based Physiatry. American Journal of Physical Medicine and Rehabilitation, 2018, 97, 855-855.	0.7	2
92	Evidence-Based Physiatry. American Journal of Physical Medicine and Rehabilitation, 2018, 97, 920-920.	0.7	2
93	Evidence-Based Physiatry. American Journal of Physical Medicine and Rehabilitation, 2018, 97, 763-763.	0.7	2
94	Evidence-Based Physiatry. American Journal of Physical Medicine and Rehabilitation, 2018, 97, 679-679.	0.7	2
95	The â€œNuts and Boltsâ€•of Evidence-Based Physiatry. American Journal of Physical Medicine and Rehabilitation, 2019, 98, 942-943.	0.7	2
96	Highestâ€Ranking Articles by Altmetric Attention Scores in Three Rehabilitation Journals. PM and R, 2020, 12, 324-326.	0.9	2
97	Research and Industry Partnerships in Physiatry. American Journal of Physical Medicine and Rehabilitation, 2021, 100, 990-995.	0.7	2
98	Evidence-Based Physiatry. American Journal of Physical Medicine and Rehabilitation, 2018, 97, 602-603.	0.7	1
99	Cochrane Corners to Enhance Access to Evidence-Based Physiatry. American Journal of Physical Medicine and Rehabilitation, 2019, 98, 87-87.	0.7	1
100	Exploring the use of educational materials for increasing participation in a stretching program: a quality improvement project in people with motor neuron disease. European Journal of Physical and Rehabilitation Medicine, 2021, 57, 78-84.	1.1	1
101	Improved Function in a Runner With Hereditary Spastic Paraparesis With Use of Extracorporeal Shockwave Therapy. American Journal of Physical Medicine and Rehabilitation, 2021, 100, e66-e68.	0.7	1
102	Osteoid Osteoma of the Spinoglenoid Notch Mimicking Cervical Radiculopathy. PM and R, 2011, 3, 280-283.	0.9	0
103	Clinical Reasoning: A 20-year-old woman with rapidly progressive weakness. Neurology, 2014, 82, e200-4.	1.5	0
104	Functional Ambulation in a Patient With Primary Lateral Sclerosis Using a Lower Extremity Robotic Exoskeleton. Archives of Physical Medicine and Rehabilitation, 2017, 98, e69.	0.5	0
105	Case 12-2019: A 60-Year-Old Man with Weakness and Difficulty Chewing. New England Journal of Medicine, 2019, 380, 1566-1574.	13.9	0
106	Reply to Letter to the Editor Regarding Paganoni S. â€œEvidence-Based Physiatry: Managing Low Back Pain Wisely.â€•Am J Phys Med Rehabil 2018;97:855. American Journal of Physical Medicine and Rehabilitation, 2019, 98, e111-e111.	0.7	0
107	Evidence-Based Physiatry. American Journal of Physical Medicine and Rehabilitation, 2019, 98, 84-85.	0.7	0